← back to search

Kevin Bielamowicz

Texas Children's Hospital · US
Area of research
Oncology · Genetics
Research interest
Research interests include CAR-T cell therapy research, Cancer Immunotherapy and Biomarkers, Glioma Diagnosis and Treatment, and Neuroblastoma Research and Treatments.
h-index
20
citations
3,392
works
168
NIH funding
primary concept
Medicine
email

Recent publications

ReNeu: A Pivotal, Phase IIb Trial of Mirdametinib in Adults and Children With Symptomatic Neurofibromatosis Type 1-Associated Plexiform Neurofibroma
Journal of Clinical Oncology 2024cited by 82position: middledoi
Clinical and biological landscape of constitutional mismatch-repair deficiency syndrome: an International Replication Repair Deficiency Consortium cohort study
The Lancet Oncology 2024cited by 58position: middledoi
Langerhans cell histiocytosis: NACHO update on progress, chaos, and opportunity on the path to rational cures
Cancer 2024cited by 20position: firstdoi
ReNeu: A pivotal phase 2b trial of mirdametinib in children and adults with neurofibromatosis type 1 (NF1)-associated symptomatic inoperable plexiform neurofibroma (PN).
Journal of Clinical Oncology 2024cited by 12position: middledoi
NFS-21. DEMOGRAPHIC, CLINICAL AND IMAGING CHARACTERISTICS OF NEWLY DIAGNOSED OPTIC PATHWAY GLIOMAS ASSOCIATED WITH NF1: RESULTS FROM THE INTERNATIONAL MULTICENTER NF1-OPG NATURAL HISTORY STUDY
Neuro-Oncology 2024cited by 2position: middledoi
NFS-24. TUMOR VOLUME IN NEWLY DIAGNOSED OPTIC PATHWAY GLIOMAS ASSOCIATED WITH NF1 (NF1-OPG): PRELIMINARY RESULTS FROM THE INTERNATIONAL MULTICENTER NF1-OPG NATURAL HISTORY STUDY
Neuro-Oncology 2024cited by 0position: middledoi
Combined Immunotherapy Improves Outcome for Replication-Repair-Deficient (RRD) High-Grade Glioma Failing Anti–PD-1 Monotherapy: A Report from the International RRD Consortium
Cancer Discovery 2023cited by 44position: middledoi
Locoregional delivery of CAR T cells to the cerebrospinal fluid for treatment of metastatic medulloblastoma and ependymoma
Nature Medicine 2020cited by 241position: middledoi
NFB-09. ENROLLMENT AND CLINICAL CHARACTERISTICS OF NEWLY DIAGNOSED, NEUROFIBROMATOSIS TYPE 1 ASSOCIATED OPTIC PATHWAY GLIOMA (NF1-OPG): PRELIMINARY RESULTS FROM AN INTERNATIONAL MULTI-CENTER NATURAL HISTORY STUDY
Neuro-Oncology 2020cited by 4position: middledoi
HER2-Specific Chimeric Antigen Receptor–Modified Virus-Specific T Cells for Progressive Glioblastoma
JAMA Oncology 2017cited by 831position: middledoi
Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma
Neuro-Oncology 2017cited by 415position: firstdoi
TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer
Cancer Research 2017cited by 156position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Nabil Ahmed · Houston Methodist2 papers (2017–2017)Meenakshi Hegde · Houston Methodist2 papers (2017–2017)Tiara T. Byrd · Baylor College of Medicine2 papers (2017–2017)Kristen Fousek · National Institutes of Health2 papers (2017–2017)Antonella Pignata · Houston Methodist1 papers (2017–2017)Rene McNall‐Knapp · University of Oklahoma Health Sciences Center1 papers (2024–2024)Tsz‐Kwong Man · Baylor College of Medicine1 papers (2017–2017)Pavel Sumazin · Children's Cancer Center1 papers (2017–2017)Nino Rainusso · Texas Children's Hospital1 papers (2017–2017)Sujith K. Joseph · Houston Methodist1 papers (2017–2017)Daniel Landi · Duke University1 papers (2017–2017)Hebatalla Samaha · Houston Methodist1 papers (2017–2017)Hans Shuhaiber · University of Florida1 papers (2024–2024)L. Mary Smith · Medical University of South Carolina1 papers (2024–2024)Alpa Sidhu · Michigan State University1 papers (2024–2024)Nicholas K. Foreman · Neurological Surgery1 papers (2024–2024)Joachim Koch · ETH Zurich1 papers (2017–2017)Michael Weber · LMU Klinikum1 papers (2024–2024)John Hicks · Baylor College of Medicine1 papers (2017–2017)Angela C. Hirbe · Sylvester Comprehensive Cancer Center1 papers (2024–2024)